Search

A research paper titled "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia" was recently published in Oncotarget's Volume 15. The paper investigates the potential of the growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 as a treatment for Doxorubicin-resistant acute myeloid leukemia (AML). The study found that MIA-602 significantly reduced cell viability in both wild-type AML cells and Doxorubicin-resistant clones. In an in vivo experiment using xenografted mice, MIA-602 treatment resulted in a reduction in tumor volume compared to the control group. The researchers suggest that GHRH antagonists like MIA-602 may offer an alternative treatment approach for AML and drug-resistant AML, potentially avoiding the side effects associated with standard chemotherapy. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 explores the synergistic cytotoxicity of ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, with the DNA alkylator thiotepa (Thio) in acute myeloid leukemia (AML) cells. The study demonstrates that the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of fludarabine, cladribine, and busulfan in AML cell lines and leukemia patient-derived cell samples. The results suggest that this combination could be used in clinical trials as part of pre-transplant conditioning regimens for AML patients undergoing hematopoietic stem cell transplantation (HSCT). The study also indicates the potential clinical relevance of the combination in overcoming ABT199/venetoclax resistance and its activity against certain cell lines. [Extracted from the article]

A recent systematic review conducted by the Hematology Unit explores the role of methylation in chronic lymphocytic leukemia (CLL) and its impact on prognosis and therapy. The study highlights the importance of epigenetic regulation in CLL biology, specifically focusing on methylation patterns and global DNA hypomethylation. The research identifies numerous genes where methylation features correlate with clinical and laboratory parameters, suggesting the potential for the development of prognostic models, predictive scores, and novel therapeutic agents. This review provides an overview of current knowledge on gene methylation and mRNA expression in CLL cases, as well as older data from past papers. [Extracted from the article]

A recent report discusses research findings on lymphoma, specifically focusing on breast lymphoma. The study highlights the rarity of this type of cancer, accounting for only 0.1% of all malignancies. The researchers emphasize the diagnostic challenges faced in distinguishing breast lymphoma from benign breast lesions and the treatment approach they followed. The paper aims to provide a review of the diagnosis, clinical features, and treatment of breast lymphoma, along with two clinical cases to enhance the reader's clinical interest. For more information, readers can refer to the article "Breast lymphoma mimicking benign breast lesions: A diagnostic challenge" in the Iraqi Journal of Hematology. [Extracted from the article]

Researchers from Penn State College of Medicine have identified a new drug target for diseases associated with the human T-cell leukemia virus type 1 (HTLV-1). By blocking a class of enzymes called kinases, which regulate cellular functions, the researchers found that cell death occurred due to the degradation of Tax, a protein essential for viral gene expression and survival of HTLV-1-infected cells. The study suggests that targeting the kinase KDR could be a potential treatment for adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Repurposing existing KDR inhibitors or developing new ones could potentially reduce the viral load of HTLV-1 and prevent disease. [Extracted from the article]

This article discusses a new method for developing and selecting models in pharmacometrics, which is important for assessing drug-biological interactions and treatment planning in diseases like Acute Myeloid Leukemia (AML). The method combines deep nonlinear mixed effect modeling and symbolic regression to derive unknown or uncertain models using longitudinal, heterogeneous data. The study found that this approach outperformed traditional models and demonstrated the validity of both the deep nonlinear mixed effect approach and the symbolic regression approach. It is important to note that this research has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Saint Joseph University in Beirut, Lebanon, has provided new data on chronic lymphocytic leukemia (CLL). The study focused on the mutational status of the immunoglobulin heavy chain (IGHV) gene, which is an important prognostic factor in CLL. The researchers specifically examined a subgroup of CLL patients classified as borderline (BL)-IGHV and found that this subgroup exhibits heterogeneity. The study suggests that further research on this subgroup is needed to optimize the management and treatment of patients with Borderline-IGHV CLL. [Extracted from the article]

A recent study conducted by researchers at Charles University in Prague compared two experimental models of primary intraocular lymphoma (PIOL) in mice to determine which model is most suitable for further research on the pathophysiology and treatment of PIOL. The study found that the model using BALB/CaNn mice and the A20 cell line was optimal for investigational research due to slower disease progression, greater ability to examine the retina, and later occurrence of exophthalmos (protrusion of the eyeball). This research was funded by the Ministry of Health, Czech Republic, Charles University Institutional Programme, MEYS CR, and the European Union. [Extracted from the article]

Researchers at the Johns Hopkins Kimmel Cancer Center have discovered that people with cancer have different amounts of repetitive DNA, called Alu elements, in their blood compared to those without cancer. Using machine learning, the researchers developed a test that can measure the amount of Alu elements in a blood sample, which can help detect cancer early. The test showed promising results, with a 98.9% specificity rate, and was able to catch 41% of cancer cases missed by existing biomarkers. This research provides a cost-effective and enhanced method for early cancer detection. [Extracted from the article]

A study conducted by researchers at King Fahd University of Petroleum and Minerals in Saudi Arabia addresses the problem of classifying cancer based on gene expression. The study focuses on two challenges: the class imbalance problem and the curse of dimensionality. The researchers propose using oversampling techniques to overcome the class imbalance problem and applying chi-square and information gain feature selection techniques to address the curse of dimensionality. The experimental results show that the proposed techniques improve the classification results, with SVM-SMOTE and random forests achieving the highest accuracy of 100%. This study provides valuable insights for early detection and diagnosis of cancer. [Extracted from the article]

A recent report from the Charles University of Prague discusses a case of pulmonary involvement in a patient with hairy cell leukemia (HCL). HCL is a rare lymphoproliferative disease characterized by an accumulation of mature B lymphocytes. In this case, the patient presented with pulmonary damage, which posed a challenge in distinguishing between infection and malignant involvement. The patient was successfully treated with interferon-alfa and cladribine, resulting in long-term remission of the underlying disease. This case highlights the complexities of diagnosing and managing pulmonary disease in patients with HCL. [Extracted from the article]

A research perspective published in Oncotarget discusses the evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma (MM), the most common primary malignancy of the bone marrow. Currently, there is no established curative treatment for MM. The Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to play a role in the pathogenesis of MM. Preclinical and clinical studies have demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Further studies will provide additional support for this promising new therapeutic approach for treating patients with MM. [Extracted from the article]

Researchers at Ningbo No.2 Hospital in China have conducted a study on targeted therapy for leukemia using nanomaterials. Leukemia is a type of malignant clonal disease that affects hematopoietic stem cells. The current drug therapies for leukemia have limitations such as low bioavailability and adverse reactions. Targeted therapy, which combines drugs with specific cancerous sites on cells, has become a popular method for leukemia treatment. Nanomedicine delivery systems, specifically nanomaterials, have the potential to improve drug efficacy through controlled size and targeted optimization of drug delivery. The study provides an overview of current therapeutic strategies for leukemia and reviews cutting-edge nanomaterials used in targeted therapy. The challenges and prospects for the future development of targeted nanomaterials in leukemia treatment are also discussed. [Extracted from the article]

Researchers from Iran University of Science and Technology have conducted a study on Chronic Lymphocytic Leukemia (CLL) cells using Atomic Force Microscopy (AFM). The study examined the morphological properties, contact mechanics, adhesion, roughness, and folding of CLL cells. The results showed that CLL cells have a spherical morphology, with an average surface roughness of 23.06 nm and 5.34% folds. The study also found that the adhesion force and work of adhesion of CLL cells were in the range of 23.2 +/- 15.6% nN and 1484.6 +/- 13.1% nJ, respectively. The research concluded that the DMT and BCP contact theories were more accurate than the Hertz theory in characterizing the mechanical contact behavior of CLL cells. The folding factor applied in the contact theories improved the accuracy of the results. The study was supported by the IRAN Nanotechnology Innovation Council (INIC) and has been peer-reviewed. [Extracted from the article]

A study conducted at Kafrelsheikh University in Egypt has explored the use of artificial intelligence (AI) in the detection of Acute Lymphoblastic Leukemia (ALL). The researchers developed two novel architectures, Knowledge Nevestro Classification (KNC) and Nevestro DenseNet (50) Attention (DAN), to improve diagnostic accuracy and streamline the diagnostic process. The results of the study showed impressive metrics, with high accuracy, sensitivity, specificity, precision, and F1-Score measures. This research has been peer-reviewed and offers promising advancements in the detection of ALL using AI technology. [Extracted from the article]

A recent study conducted by researchers at JSS Academy of Higher Education and Research in Mysuru, India, focuses on finding alternative treatments for leukemia, a global health concern. The researchers investigated the role of p53, a tumor suppressor that regulates cell division, and aimed to identify small molecule modulators of Mdm2 and Pirh2, which are proteins involved in the p53 pathway. Through in silico and in vitro studies, the researchers synthesized compounds that showed potent anti-proliferative effects and significant cytotoxicity against leukemia cells. The study presents these novel compounds as potential candidates for further optimization and preclinical studies as effective anticancer therapies. [Extracted from the article]

A recent report from Sciences College discusses the role of NAD-dependent enzymes, such as CD38, PARP1, and SIRT1, in patients with different types of leukemia. The study found that the levels of these enzymes were significantly higher in leukemia patients compared to healthy individuals. The researchers concluded that these enzymes could serve as predictive indicators of the disease and potentially be used in future treatments. The full report can be accessed for free online. [Extracted from the article]

A study conducted by researchers at Zhejiang Chinese Medical University explores the role of minimal residual disease (MRD) and serum free light chain ratio in the management of multiple myeloma (MM). The researchers highlight the importance of MRD assessment for risk assessment in MM patients and the significance of serum free light chain levels and their ratio in evaluating disease burden and changes in MM. The study reviews and examines the characteristics, advantages, disadvantages, and interrelation of MRD and serum free light chain ratio in the treatment of MM. This research provides valuable insights into the management of multiple myeloma. [Extracted from the article]

Researchers from the University of South China have conducted a study on hematopoietic cell kinase (Hck) and its role in cancer progression. Hck, a non-receptor tyrosine kinase, is closely associated with the development of various human diseases, particularly cancer. The study explores how Hck affects the proliferation, migration, and apoptosis of cancer cells, as well as its interactions with other pathways. The researchers also discuss the implications of Hck in solid tumors and hematological malignancies. They highlight the potential of Hck inhibitors in the diagnosis and treatment of malignant tumors, emphasizing the need for further investigation and the development of specific inhibitors. [Extracted from the article]

Researchers at Beth Israel Deaconess Medical Center have explored the potential of machine learning (ML) in the field of healthcare, specifically in relation to cancer-associated thrombosis (CAT). ML has the ability to improve patient outcomes, streamline healthcare delivery, and drive innovation. However, there are challenges that need to be addressed, such as the availability of high-quality datasets, overfitting, limited generalizability, and the risk of bias. To effectively develop ML in the health sector, collaboration between clinicians, computer scientists, regulatory bodies, and patient groups is crucial. [Extracted from the article]

Researchers at Fuzhou University in Fujian, China have developed a deep learning model fusion algorithm for the diagnosis of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The algorithm uses hematoxylin-eosin (H&E) whole slide images (WSIs) to accurately diagnose MALT lymphoma, which is a type of malignant tumor originating from the lymphohematopoietic system. The proposed framework achieved an accuracy of 98.53% using image patches and 94.96% on 258 WSIs, demonstrating its potential use in clinical practice. The research was funded by the National Natural Science Foundation of China and the Fujian Health Commission. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences conducted a systematic review and meta-analysis to explore the prognostic significance of ASXL1 mutations in acute myeloid leukemia (AML). They analyzed 27 studies with a total of 8,953 participants and found that ASXL1 mutations were associated with a poor prognosis in AML patients. However, they recommend further studies to investigate the impact of different ASXL1 mutations on prognosis. This research provides valuable insights into the potential prognostic factors in AML. [Extracted from the article]

A recent study conducted at the University of Aizu has developed a computer-aided diagnosis system to improve the accuracy of acute leukemia diagnosis using microscopic blood smear images. The system utilizes a two-staged deep learning-based approach, incorporating pretrained deep neural network branches and feature fusion techniques. The experimental findings showed that the proposed method achieved an accuracy of 99.3% in detecting acute leukemia and 100.0% accuracy in detecting acute lymphocytic leukemia. The researchers believe that this architecture can be adopted by clinics for quick and automated diagnosis. [Extracted from the article]

A recent study conducted by researchers at Fondazione IRCCS Istituto Nazionale Tumori in Milan, Italy, explores the use of Proton Beam Therapy (PBT) in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). NRSTS are rare and aggressive tumors that present complex clinical management challenges. The study suggests that PBT may be a suitable therapeutic option for these patients, as it can minimize radiation-induced side effects and improve local control while reducing toxicity and improving quality of life. However, more research is needed to determine the therapeutic superiority of PBT over other photon techniques. The study emphasizes the importance of a comprehensive collaborative approach and shared guidelines to optimize the use of PBT resources. [Extracted from the article]

A recent study led by researchers from Mass General Brigham and Beth Israel Deaconess Medical Center has identified proteins in the blood that could help predict the risk of liver cancer years before diagnosis. Liver cancer is often diagnosed at a late stage, making treatment options limited. The study utilized proteomics to develop a prediction model for early detection of liver cancer, using a high-throughput proteomics platform to measure protein levels in blood samples. The researchers identified 56 plasma proteins that were significantly elevated in individuals with liver cancer compared to control individuals, and their predictive model showed greater accuracy than traditional risk factors. Further validation in larger and more diverse patient populations is needed. [Extracted from the article]

A study conducted by researchers at Sharda University in Greater Noida, India, focused on the design, synthesis, and biological screening of methyl-piperidine-phenyl-nicotinamide derivatives as potential anticancer agents. The compounds (9a), (9e), and (9k) demonstrated potent anticancer activity against Acute Myeloid Leukemia and Chronic Myeloid Leukemia cell lines. Docking studies revealed that these compounds exhibited good binding affinity for ABL1 kinase, and they also showed favorable in silico ADME profiles. The research suggests that these derivatives hold promise for the development of new anticancer drugs in oncology programs. [Extracted from the article]

A recent study conducted by researchers at Al-Farabi Kazakh National University focused on acute lymphoblastic leukemia (ALL), which is the most common cancer in children and teenagers. The study analyzed chromosomal abnormalities in 1,269 children with ALL and found various translocations and mutations. The researchers emphasized the importance of cytogenetic studies in diagnosing and predicting outcomes for children with ALL. The study's findings align with existing scientific literature and highlight the significance of understanding chromosomal aberrations in this disease. [Extracted from the article]

Researchers from the University of Science and Technology China have developed a lightweight deep learning model called AMLNet for the identification of acute myeloid leukemia (AML) cells. The model, based on the ShuffleNet V2 architecture, demonstrates high performance and low computational consumption, making it suitable for practical diagnosis scenarios with limited computational power. The AMLNet model achieved optimal classification performance with an AUC of 0.9935%, sensitivity of 63.91%, and accuracy of 96.43%. This research highlights the potential of lightweight deep learning models in improving the accuracy of leukemia typing and reducing the workload of specialized physicians. [Extracted from the article]

Researchers from Saveetha Engineering College in Chennai, India have developed an efficient leukemia detection model using deep learning approaches. The model utilizes a Multiscale Trans-Res-Unet3+ (MTResUnet3+) Network for region segmentation, followed by feature extraction and selection using the Election-Based Chameleon Swarm Algorithm (E-CSA). The Multiscale Adaptive and Attention-based Dilated Convolutional Neural Network (MAA-DCNN) is then used to detect leukemia, with parameter optimization done using hybrid E-CSA. The performance of the model was analyzed through simulation analysis and compared to conventional detection models and existing algorithms. This research has been peer-reviewed. [Extracted from the article]

A recent study conducted at the Fundeni Clinical Institute in Bucharest, Romania, focused on the complications associated with the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapy for acute promyelocytic leukemia (APL). The study found that while ATRA plus ATO therapy has shown excellent outcomes in terms of remission rates and overall survival, it is associated with a range of distinctive toxicities, including differentiation syndrome, liver toxicity, QT interval prolongation, and neurotoxicity. However, these adverse events are generally manageable and reversible. The study also noted a lower incidence of secondary neoplasms compared to standard chemotherapy. Further research is needed to understand the long-term effects of the ATRA plus ATO regimen. [Extracted from the article]

A research report from the Vellore Institute of Technology in India discusses the challenges of accurately diagnosing malignant lymphoma, a form of cancer that affects the lymphatic system. The researchers propose using ensemble and non-ensemble transfer learning models with pre-trained weights from various neural networks to improve diagnostic accuracy. Testing on a dataset of different lymphoma subtypes showed exceptional accuracy, with certain models achieving over 90% accuracy and the proposed ensemble model achieving 99% accuracy. The study demonstrates the potential of this approach for precise lymphoma diagnosis in real-world medical applications. [Extracted from the article]

A recent report from Hebei Medical University in China discusses a rare case of intravascular large B-cell lymphoma (IVLBCL) occurring alongside lung adenocarcinoma. The patient presented with symptoms of diarrhea, fever, and cough, and a CT scan revealed abnormalities in the right lung. After further testing and surgery, the patient was diagnosed with invasive nonmucinous adenocarcinoma of the lung with IVLBCL. The researchers emphasize the importance of understanding the clinicopathological characteristics of this rare combination to prevent misdiagnosis. [Extracted from the article]

A recent study conducted at the University Hospital of Lyon explores the use of small molecule menin inhibitors as novel therapeutic agents for acute myeloid leukemia (AML) with specific genetic abnormalities. The study highlights the clinical value of genomic abnormalities in AML and the development of targeted therapies that have improved patient outcomes. Phase 1/2 clinical trials have shown the efficacy and tolerability of menin inhibitors such as SNDX-5613 and KO-539. The research reviews the progress in exploring menin-KMT2A interactions and their potential application in the treatment of acute leukemias. [Extracted from the article]

Researchers from Kerman University of Medical Sciences in Iran have published a study on the effect of extracellular vesicles (EVs) derived from peripheral blood mononuclear cells on the growth and proliferation of the chronic myelogenous leukemia cell line K562. The study found that the EVs did not have an inhibitory effect on the growth of the leukemia cells. The researchers concluded that tumor-derived EVs may support tumor cell growth by communicating with each other through their EVs. Further information on the study can be obtained from the Department of Hematology and Medical Laboratory Sciences at Kerman University of Medical Sciences. [Extracted from the article]

A report from the Department of Oncology in Bronx, New York discusses the use of Venetoclax (VEN) in the treatment of acute myeloid leukemia (AML). While VEN has shown promise in treating AML and chronic lymphocytic leukemia (CLL), there is a heterogeneous response, with some patients not responding to the treatment or relapsing shortly after. The report explores the mechanisms of action of VEN and the various factors that can contribute to resistance, including mutations in BCL-2 and BAX proteins, TP53 mutations, and changes in mitochondrial structure and metabolism. The researchers also discuss potential combination therapies and other novel approaches to overcome VEN resistance. [Extracted from the article]

A new report from the Chinese Academy of Medical Sciences discusses the case of a patient with chronic myeloid leukemia (CML) who experienced abnormally elevated platelets and cerebral hemorrhage. The patient underwent surgery to remove the hematoma and was subsequently diagnosed with accelerated CML. Treatment with flumatinib through a jejunostomy tube successfully controlled the patient's condition. The report aims to provide clinicians with a warning and reference for similar cases. [Extracted from the article]

Researchers from MATS University in Raipur, India have proposed a novel method for classifying medical data related to cancer. The method involves using Principal Component Analysis (PCA) for feature extraction and modified particle swarm optimization (MPSO) for feature selection. The researchers found that their method produced better results compared to existing methods, with optimized results for SVM, KNN, and Naive Bayes classifiers. The classified data is then stored in cloud IoT sensors. This research provides valuable insights into the classification of gene expression-based microarray medical datasets for cancer diagnosis. [Extracted from the article]

Researchers at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy have presented data on plasmablastic lymphoma, a rare and aggressive form of lymphoma. The research aims to provide a comprehensive understanding of the diagnosis and management of this disease. The review covers topics such as epidemiology, etiology, clinicopathological characteristics, differential diagnosis, prognostic variables, and the impact of plasmablastic lymphoma on specific populations. Despite advances in understanding, the prognosis for this disease remains poor, although recent reports suggest some improvement. [Extracted from the article]

A study conducted at the University of Tsukuba in Japan compared different fludarabine-containing conditioning regimens used in cord blood transplantation (CBT) for myeloid malignancies. The study analyzed data from 1395 cases and found that the combination of fludarabine, melphalan, and low-dose total-body irradiation offered the best survival rate (67%) with the lowest relapse rate and nonrelapse mortality after CBT. The researchers also observed fewer deaths from infection with this combination. The study suggests that an appropriate combination of fludarabine and alkylating agents could improve the outcome of future CBTs. [Extracted from the article]

A new research perspective published in Oncotarget's Volume 15 titled "Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma" explores the potential of using changes in bone marrow adipose tissue (BMAT) as an early indicator of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM). The study found that MGUS patients who developed MM had decreased bone marrow adipocyte (BMAd) density and a shift towards increased BMAd size and roundness compared to non-progressing MGUS patients. These early changes in BMAT could potentially enable timely interventions and personalized treatment strategies. The AI-based approach used in the study for histological analysis of bone marrow biopsies was found to be cost-effective and fast, making it feasible for clinical implementation. [Extracted from the article]

A recent study conducted by researchers at Pomeranian Medical University in Szczecin, Poland, explored the potential benefits of vitamin D and vitamin K supplementation in the treatment of multiple myeloma (MM), a type of plasma cell malignancy. The researchers found that vitamin D and vitamin K have anti-inflammatory and anti-cancer properties, and they may induce epigenetic changes that reduce the proliferative potential of MM cells and prevent the development of resistance to certain drugs. However, further studies are needed to confirm these findings and establish new supplementation recommendations for adjuvant therapy. This research was supported by the National Science Centre Grant Miniatura and the Minister of Science And Higher Education. [Extracted from the article]

A recent study conducted by Trinity College Dublin has investigated the potential use of certain compounds in the treatment of chronic lymphocytic leukemia (CLL) and Burkitt's lymphoma (BL). The researchers synthesized a series of compounds and found that some of them demonstrated potent antiproliferative effects in both CLL and BL cell lines. These compounds offer potential for further development as novel chemotherapeutics for CLL. The study provides valuable insights into potential treatment options for these types of lymphoma. [Extracted from the article]

A report from Northeastern University in Shenyang, China discusses new findings on lymphoma segmentation using positron emission tomography/computed tomography (PET/CT). The research proposes a novel method of lymphoma segmentation on multi-temporal resolution PET (MTR-PET) images, focusing on the differences between lymphoma and other tissues on different temporal resolution PET images. The study utilizes statistical analysis and CNN networks for accurate lymphoma segmentation. The research concludes that MTR-PET images can significantly improve the performance of lymphoma segmentation. [Extracted from the article]

A recent study published in Cell Reports has identified a complex network of genes that may be manipulated to target and kill off Acute Myeloid Leukemia (AML) cancer cells. The researchers used advanced screening tools to identify gene regulatory networks (GRNs) specific to FLT3-ITD mutated AML cells. By targeting key factors within these networks, such as the TF RUNX1, the researchers were able to disrupt the network and potentially lead to the death of cancer cells. This research provides valuable insights into potential targets for AML treatment and was funded by the MRC, Leukaemia UK, and Blood Cancer UK. [Extracted from the article]